B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 162.7 DKK -1.39% Market Closed
Market Cap: 12.8B DKK

EV/EBIT
Enterprise Value to EBIT

9.5
Current
8.4
Median
3.7
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
9.5
=
Enterprise Value
10.9B DKK
/
EBIT
1.1B DKK
Market Cap EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
12.7B DKK 9.5
FR
Pharnext SCA
OTC:PNEXF
6T USD -208 527.2
US
Abbvie Inc
NYSE:ABBV
371.2B USD 25.8
US
Amgen Inc
NASDAQ:AMGN
167.2B USD 29.2
US
Gilead Sciences Inc
NASDAQ:GILD
132.3B USD 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.1B USD 27.9
US
Epizyme Inc
F:EPE
94.1B EUR -521.3
AU
CSL Ltd
ASX:CSL
123B AUD 21.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.1B USD 11.9
US
Seagen Inc
F:SGT
39.3B EUR -55.3
NL
argenx SE
XBRU:ARGX
34B EUR -2 413.4
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 20
9.5
-18%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.8
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.2
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.8
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 413.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
12
2-Years Forward
EV/EBIT
6.4
3-Years Forward
EV/EBIT
9.2